- Abbott has adjusted its full-year EPS forecast to a range of $5.10 to $5.20, slightly refining the previous range of $5.05 to $5.25. Analysts had estimated $5.16.
- For the second quarter, Abbott reported an adjusted EPS of $1.26, surpassing both last year’s $1.14 and analyst estimates of $1.25.
- Organic sales grew by 6.9%, slightly below last year’s 7.4% and also below the estimated 7.03%.
- Excluding COVID-19 testing-related sales, organic sales increased by 7.5%, compared to last year’s 9.3% and the estimate of 7.44%.
- Net sales rose to $11.14 billion, a 7.4% increase year-over-year, exceeding the $11.06 billion estimate.
- Nutrition sales were $2.21 billion, showing a 2.9% growth year-over-year, but slightly below the estimated $2.24 billion.
- Diagnostics sales decreased by 1% to $2.17 billion, which was lower than the estimated $2.21 billion.
- Established pharmaceuticals sales reached $1.38 billion, a 6.9% increase year-over-year, slightly above the $1.37 billion estimate.
- Medical devices sales saw a robust growth of 13%, amounting to $5.37 billion, surpassing the $5.23 billion estimate.
- Diabetes care sales significantly increased by 20%, reaching $1.98 billion, exceeding the $1.93 billion estimate.
- Analyst recommendations for Abbott consist of 20 buys, 9 holds, and 1 sell.
Abbott Laboratories on Smartkarma
Abbott Laboratories is receiving positive analyst coverage on Smartkarma from Baptista Research. In their report titled “Abbott Laboratories Expansion Play: Can Global Growth & Local Manufacturing Drive the Next Surge?”, Baptista Research highlights the company’s impressive first quarter 2025 earnings results. Despite global challenges like new tariff policies and economic uncertainties, Abbott’s diversified model and strategic framework have supported strong operational performance. The company has achieved high single-digit sales growth and double-digit earnings per share growth. Baptista Research is conducting an independent valuation of Abbott Laboratories using a Discounted Cash Flow methodology to evaluate potential future price influences.
In another analysis by Baptista Research titled “Abbott Laboratories: An Insight Into Its Medtech & Diagnostic Growth Trajectory & Why It May Not Be Enough To Warrant A ‘Buy’ Rating!”, Abbott Laboratories demonstrated solid financial performance in the fourth quarter of 2024, continuing a trend of robust growth seen throughout the year. With a strong sales growth of 10% excluding COVID-19 testing and a full-year increase of 9.5%, Abbott’s success was particularly driven by advancements in segments like Adult Nutrition and Medical Devices, including innovative glucose monitoring systems. Baptista Research provides a detailed look into Abbott Laboratories‘ growth trajectory and reasons why it may not yet warrant a ‘buy’ rating, offering valuable insights into the company’s future prospects.
A look at Abbott Laboratories Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbott Laboratories, a leading healthcare company, has garnered predominantly positive ratings in key areas according to Smartkarma Smart Scores. With a notable score of 4 in Growth and Resilience, Abbott is positioned for long-term stability and potential expansion in its product offerings. The company’s strong emphasis on innovation and development bodes well for continuous growth in the future.
While Value and Dividend scores are slightly lower at 2 and 3 respectively, Abbott Laboratories‘ overall outlook remains promising. Combined with a Momentum score of 3, indicating a steady pace of growth, investors may find Abbott to be an attractive option for a well-rounded investment in the healthcare sector. With its diversified line of healthcare products sold globally, Abbott Laboratories demonstrates a solid foundation for sustained success in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
